Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic

Gines Escolar1 | Maribel Diaz-Ricart1 | Jeffrey McCullough2

1Department of Hematopathology, Centre Diagnostic Biomedic, Hospital Clinic, Barcelona, Spain
2Global Blood Advisor, adjunct Professor, Arizona State University, USA

Correspondence
Gines Escolar, Department of Hematopathology, Hospital Clinic of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Email: gescolar@clinic.cat

Funding information
This study was partially supported by German José Carreras Leukaemia Foundation (03R/2019), Integrated Project in Health Institutes (PIE15/00027), and FIS P119/00888 from the Instituto de Salud Carlos III, Spanish Government; 2017-SGR671 from Generalitat de Catalunya, and CERCA Program of the Generalitat de Catalunya.

Abstract
Standard platelet concentrates (PCs) stored at 22°C have a limited shelf life of 5 days. Because of the storage temperature, bacterial contamination of PCs can result in life-threatening infections in transfused patients. The potential of blood components to cause infections through contaminating pathogens or transmitting blood-borne diseases has always been a concern. The current safety practice to prevent pathogen transmission through blood transfusion starts with a stringent screening of donors and regulated testing of blood samples to ensure that known infections cannot reach transfusion products. Pathogen reduction technologies (PRTs), initially implemented to ensure the safety of plasma products, have been adapted to treat platelet products. In addition to reducing bacterial contamination, PRT applied to PCs can extend their shelf life up to 7 days, alleviating the impact of their shortage, while providing an additional safety layer against emerging blood-borne infectious diseases. While a deleterious action of PRTs in quantitative and qualitative aspects of plasma is accepted, the impact of PRTs on the quality, function, and clinical efficacy of PCs has been under constant examination. The potential of PRTs to prevent the possibility of new emerging diseases to reach cellular blood components has been considered more hypothetical than real. In 2019, a coronavirus-related disease (COVID-19) became a pandemic. This episode should help when reconsidering the possibility of future blood transmissible threats. The following text intends to evaluate the impact of different PRTs on the quality, function, and clinical effectiveness of platelets within the perspective of a developing pandemic.

Keywords
in vitro quality, pathogen reduction technologies, platelet concentrates

1 | INTRODUCTION

The safety procedures to prevent transfusion-related pathogen transmission start with careful screening of donors and include regulated blood testing for known pathogens. Tests introduced for the detection of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C virus (HCV) in donor samples have dramatically...
improved the safety of transfused blood products. Additional tests have been progressively implemented to detect other blood-borne viral and parasitic infections. Traditional methods of donor screening and mandated testing have limited ability to prevent emerging infectious agents like the dengue or chikungunya viruses and parasites such as *Plasmodium falciparum* or *Leishmania*, from reaching blood therapeutic products. It is increasingly complex like the dengue or chikungunya viruses and parasites such as *Plasmodium falciparum* or *Leishmania*, from reaching blood therapeutic products.2 It is increasingly complex and impractical to respond to new pathogen threats by simply adding additional detection tests, and the risk of bacterial contamination during platelet storage remains significant. Pathogen reduction technologies (PRTs) provide an additional safety layer to reduce the risk of emerging infections undetectable through current testing.1,4 PRTs initially introduced for plasma products have substantially improved safety, and their potential deleterious action on the plasma quality has not been challenged. PRTs were later adapted to treat platelet products with a triple-intent: to prevent bacterial contamination,6 to prolong the shelf life of platelet concentrates (PC) up to 7 days, and to provide an additional safety layer against emerging blood-borne infectious diseases. In contrast to their detrimental actions on the quality of plasma products, PRT-induced changes in platelet products are intensely scrutinized. The following text will attempt to place in perspective the advantages and disadvantages of PRT applied to platelet products. The contents of this review are of particular relevance during the COVID-19 pandemic as these technologies may protect the blood supply from future blood-borne epidemic threats.

## 2 METHODOLOGIES—AVAILABILITY AND EFFECTIVENESS IN PATHOGEN REDUCTION

Three technologies are currently available for pathogen reduction in PCs, each utilizing exposure to UV light. Two of these technologies, INTERCEPT and MIRASOL, introduce a photosensitive compound to PCs before activation with UV. The third technology, THERAFLEX, uses short-wave UV alone.

The INTERCEPT Blood System (Cerus Corporation, Concord, CA, USA) obtained the CE mark for platelets in 2002. This technology uses amotosalen as a photosensitizer, before its activation by exposure to UVA illumination (320–400 nm). A removal process reduces residual amotosalen to trace levels avoiding possible toxicity.1,7 INTERCEPT PRT, in use for >18 years in over 30 countries, has been approved for platelets by the US Food and Drug Administration (FDA).

MIRASOL (Terumo BCT, Lakewood, CO, USA)8 uses riboflavin (vitamin B2) as a photosensitizer, followed by activation at UVA-UVB spectral regions (265–370 nm). Riboflavin does not need to be removed from the exposed product. This methodology obtained the CE mark for platelets in 2007 and is being used in >20 countries.

THERAFLEX UV-Platelets (MacoPharma, Mouvaux, France), developed more recently, does not require a photosensitive agent. This PRT uses short-wave ultraviolet light (UVC wavelength range 200–280 nm) applied to PCs under agitation. This technology obtained CE mark for platelets in 2009 and was recently evaluated in the clinical setting.9

PRTs are unlikely to sterilize the transfusion product to the point of zero risk of pathogen transmission,10 and therefore, the “reduction of pathogen load” is a better definition of their objective.11,12 Extensive literature has confirmed that the PRTs referred to in this text have demonstrated substantial benefits by inactivating high levels of a range of clinically relevant bacteria, viruses, and parasites, in both plasma and PCs. Comprehensive reviews on the three technologies are available.13–19 Furthermore, these PRTs have shown effectiveness at mitigating transmission of West Nile virus and coronaviruses.4,19–21 MIRASOL was recently shown to be effective at reducing SARS-CoV-2 in plasma, platelets, and whole blood.22,23 INTERCEPT does also efficiently inactivate SARS-CoV-2 in human plasma and similar actions could be expected for THERAFLEX.

## 3 IN VITRO QUALITY OF PLATELET CONCENTRATES

The term “storage lesion” was coined to describe a series of structural and functional alterations during the storage of red cells and has also been applied to PCs. This lesion starts early during the process of collection, increases progressively during storage, and compromises the in vivo function of transfused platelets.24 Improvements in plastic containers, additive solutions, and collection procedures have alleviated the problem, but have not substantially improved the quality of PCs stored for longer periods.

Tests to evaluate the in vitro quality of stored platelets fall in two major groups: (a) indirect parameters of platelet quality (platelet count, metabolism, structure, presence of receptors or activation markers); or (b) direct measurements of adhesive, aggregating, and procoagulant activities of platelets.25 Metabolic changes in PCs stored for 5 days are characterized by reduction in glucose levels, augmented lactate production, and pH lowering, indicating enhanced anaerobic metabolism. These metabolic changes are associated with alteration of platelet morphology, reductions in glycoproteins,
enhanced expression of platelet activation- and apoptotic markers, and reduced functional responses.

For the purpose of this review, we have identified a total of 53 relevant publications, 20 evaluating the in vitro quality of PCs subjected to INTERCEPT,26–45 23 using MIRASOL,46–68 5 using THERAFLEX,19,69–72 and 5 studies that have compared INTERCEPT versus MIRASOL.73–77 Details of these studies are summarized in the Supplemental Table 1.

3.1 Impact of PRTs on biological and metabolic indicators

INTERCEPT enhances anaerobic metabolism in treated PCs. Increased glucose consumption, lactate accumulation, and acidification are consistently reported in buffy-coat28–30,32,35,36,38,39 or apheresis PCs27,37–39,41–43 after exposure to INTERCEPT. These changes were followed by alterations in platelet morphology, slight reductions in swirling, and altered resistance to hyperosmotic shock (HSR). Moderate reductions in GPIb with the activation of GPIb-IIIa,37,38,42,43 with enhanced expression of P-selectin, have been confirmed by numerous investigators.27,28,30–33,35,36,38,39,42–45 The increased expression of P-selectin parallels enhanced signs of apoptosis with the exposure of anionic phospholipids, binding of annexin-V, and release of microparticles.32,33,35,39,41,42,45 Introduction of classic or newer formulations of platelet additive solutions (PASs) does not prevent the deterioration observed after INTERCEPT.28,30,37,39,42–45 A reduction of citrate concentration in PAS may slightly reduce platelet activation.

Alterations induced by MIRASOL are similar to those observed with INTERCEPT—increased anaerobic metabolism and subsequent acidification after treatment of buffy-coat,52–54,56,63,66,68 or apheresis-derived PCs.51,55,57–59 Metabolic changes were accompanied by morphological alterations, reductions in swirling, and altered HSR.48,52,53,55,57–60,63,64,66,68 Moderate reductions in GPIb with the activation of GPIb-IIIa have been similarly reported after MIRASOL exposure,48,52,53,55,57–60,63,64,66,68

![Proportion of studies evaluating different in vitro quality parameters in PCs exposed to PRTs](image-url)

**FIGURE 1** Bar diagrams represent comparative percentages of in vitro quality parameters assessed in the publications evaluated in this review. As shown by the double pointed arrows the majority of studies have concentrated on indirect markers of platelet quality (black arrows). Because of their higher complexity, fewer proportions of studies have concentrated on the evaluation of functional parameters of platelets in the pathogen-reduced concentrates (red arrows). Differences in qualitative aspects explored for a certain PRT that have not been evaluated by other technologies may depend on tests available at the time of the studies or expertise of research groups with them. Data were compiled from a total of 20 publications on INTERCEPT, 23 on MIRASOL, 5 on THERAFLEX, and 5 studies that have compared INTERCEPT versus MIRASOL (GPS = glycoproteins)
| References | PRT | Metabolism | Morphology | Flow Cytometry/activation markers | Functional tests | Comment | Conclusions |
|------------|-----|------------|------------|-----------------------------------|------------------|---------|-------------|
| 8-MOP Procaccini et al. | Volunteers, platelet-rich plasma exposed to psoralen + UVA | — | — | ADP ↓, Coll↓ Risto, Arachidonic Acid | Abnormal platelet aggregation to ADP and Coll with elevated concentrations of 8-MOP | No detectable abnormality in platelet function in vivo after ingestion |
| INTERCEPT versus Control Picker et al. | Buffy-coat 7 days | Glucose ↓ 1–7 days Lactate ↑ 3–7 days pH ↓ 1–7 days | HSR = 1–7 days Swirl = 1–7 days | CD62 ↑ 3–7 days | Risto ↓ 3–7 days | Aggregation decreased significantly in all PCs during storage, with lower values in PRT-units | Platelet count ↓ PRT caused various alterations of in vitro data. Although significant these changes were relatively modest |
| INTERCEPT Different bags Jansen et al. | 7–11 days PAS-III | Glucose ↓ 7 days Lactate ↑ 4–7 days ATP ↓ 7 days | HSR = 2–7 days | CD62 progress from 2–11 days (n.s) ANV ↑ from 2–11 days | ADP = (low) Coll ↓ 2,7 days Thrombin ↓ 2,4 days | Significant reduction in aggregation capacity with collagen and thrombin |
| INTERCEPT Lozano et al. | Buffy-coat 5–7 days | — | — | — | Global Test Perfusion | Adhesive and aggregating capacities under flow conditions remained well preserved for up to 7 days | Platelet Count ↓ 10% after 5 days |
| INTERCEPT Johnson et al. | INTERCEPT versus Control Buffy-coat 7 days SSP+ | Glucose ↓ Lactate ↑ pH ↓, ATP ↓ | CD62 ↑ 5–7 days Cytokines RANTES ↑ | Collagen ↓ ADP= | Alterations in aggregating responses were more evident from day 5 of storage | Platelets suspended in SSP + with reduced plasma carryover are of suitable in vitro quality following PRT.
### TABLE 1 (Continued)

| References      | PRT          | Metabolism   | Morphology | Flow Cytometry/activation markers | Functional tests | Comment                                           | Conclusions |
|-----------------|--------------|--------------|------------|-----------------------------------|------------------|---------------------------------------------------|-------------|
| INTERCEPT       | INTERCEPT    | HSR ↓ 7 days | PAC-1 ↑ 7  | CD62 ↑ ANV                        | ADP ↑ 7 days      | Variable alterations of PLT aggregation.           | Platelet count ↓ |
| Abonnenc et al. | versus Control or UV | — | 7 days     | 7 days                            | Col ↑ 2 days ↑    | % of adherent platelets increased on days 4 and 7 compared to control units. | UV alone make negligible contributions to the changes in aggregation observed |
| Buffy-coat      |              |              | CD42 ↓ 7   | days                              | AA = TRAP = + Static adhesion on fibrinogen |                                      |
| PAS Intersol    |              |              |            |                                   |                  |                                                   |
| INTERCEPT       | INTERCEPT    | —            | CD42b ↓    | —                                 | ANV ↑ =          | Collagen ↓ 1 day Thrombin ↓ 1 day + Microfluidic on collagen and VWF ↓ | Phosphorylation p38 ↑ (apop) Bak ↑ |
| Stivala et al.  | versus Control Apheresis 7 days | — | —         |                                   |                  | Reduced platelet aggregation. Reduction in platelet coverage on Coll and VWF surfaces In vivo Survival | Enhanced apoptosis and accelerates clearance |
| INTERCEPT       | INTERCEPT    | —            | —          |                                   |                  |                                                   |
| versus Control Apheresis 7 days | — | —         | —          |                                   |                  |                                                   |
| MIRASOL         |              | —            | CD42 ↑ 3–5 | days                              | ANV ↑ 3–5 days   | Global Tests Perfusion studies with blood flowing through damaged vessel segments | Treatment with 6.2 J/ml preserve adhesive and cohesive functions of platelet to levels compatible with those observed in control PCs. |
| Perez-Pujol et al. 47 | Apheresis Impact of UV intensities 6.2 or 12.3 J 5 days | — | —         |                                   |                  |                                                   |
| MIRASOL         |              | —            | —          |                                   |                  |                                                   |
| versus Control or G-irradiation Apheresis 7 days | Glucose ↓ Lactate ↑ ↑ pH↓ 5–7 days | — | Swirl ↑ 5–7 days | — | CD62 ↑ 5–7 days | — | Risto | — | Platelet count ↓ (due to dilution) modifications similar to G-irradiation M slightly better than historical data with I |
| Picker et al. 48 |              |              | —          |                                   |                  |                                                   |
| MIRASOL         |              | —            | —          |                                   |                  |                                                   |
| versus Control or Buffy-coat 8 days | pH ↓ 3–8 days | Swarm ↑ = control MPV ↑ 2–8 days | — | — | — | ADP ↑ = Coll ↓ 6–8 days TRAP ↓ 3–8 days + TEG | Impaired aggregation. Reductions in maximum clot strength | Platelet count ↓ 7–8 days |
| Ostrowski et al. 44 |              |              |            |                                   |                  |                                                   |
| References          | PRT                  | Metabolism                      | Morphology | Flow Cytometry/activation markers | Functional tests | Comment                                                                 | Conclusions                                      |
|---------------------|----------------------|--------------------------------|------------|----------------------------------|------------------|-------------------------------------------------------------------------|--------------------------------------------------|
| MIRASOL             | versus Control Apheresis | Glucose ↓ 3–7 days | Swirl ↓ 5–7 days | GPIb ↓ 7 days | CD62 ↑ 3 days | ANV ↑ 3, 7 days | Global test | Perfusion studies | Blood flowing through damaged vessel segments | (maximum amplitude, no changes in initial fibrin formation, clot growth rate (alpha) had a minimal influence on clot formation. |
| Galan et al.        | 7 days various PAS-III versus PAS-IIIM | Lactate ↑ 3–7 days | pH ↓ 5–7 days variations among PAS | GPIIb-IIIa ↑ 7 days | CD63 ↑ 7 days | Global test | Perfusion studies | Blood flowing through damaged vessel segments | PCs stored in PAS presented similar reactivity than that observed for untreated PCs. Moderate reductions in cohesive properties in PRT-PAS-III PCs, but not in PRT-PAS-IIIM PCs, at day 7. Quality was reasonably preserved in PCs stored in PAS for 5 days. PAS-IIIM better than PAS-III at 7 days |
| MIRASOL             | versus Control Buffy-coat | Glucose ↓ 2–7 days | — | GPIIIa = | CD62, CD63 ↑ 2–7 days | ANV ↑ 2–7 days | Mitochondrial permeability | = CD40L = | ADP = Coll ↓ 5–7 days | Platelet aggregation with ADP low but maintained through storage. Reduced platelet aggregation with Coll. | M treatment and storage in PAS is no more detrimental than storage in plasma. |
| Johnson et al.      | 7 days PAS-IIIM       | Lactate ↑ 2–7 days | pH ↓ (5–7 days) | Swirl ↓ 7–8 days | CD62 1–8 days | ANV ↑ 5–8 days | Coll ↓ 1 day = 5–8 days | TRAP ↓ 5–8 days + Cone-Plate Impact-R | Reduced platelet aggregation. Surface covered in the Impact-R decreases with storage time, but similar to controls | Platelet Count ↓ 8 days. Results with M in PAS were comparable to plasma preserving ATP and mitochondrial function. |
| MIRASOL             | versus Control Apheresis | Glucose ↓ 1–8 days | Swirl ↓ 7–8 days | — | CD62 1–8 days | ANV ↑ 5–8 days | Coll ↓ 1 day = 5–8 days | TRAP ↓ 5–8 days + Cone-Plate Impact-R | Reduced platelet aggregation. Surface covered in the Impact-R decreases with storage time, but similar to controls | Platelet Count ↓ 8 days. Results with M in PAS were comparable to plasma preserving ATP and mitochondrial function. |
| Picker et al.       | 8 days PAS SSP+       | Lactate ↑ 1–7 days | pH ↓ 1–8 days | ATP ↓ 8 d | CD62 1–8 days | ANV ↑ 5–8 days | Coll ↓ 1 day = 5–8 days | TRAP ↓ 5–8 days + Cone-Plate Impact-R | Reduced platelet aggregation. Surface covered in the Impact-R decreases with storage time, but similar to controls | Platelet Count ↓ 8 days. Results with M in PAS were comparable to plasma preserving ATP and mitochondrial function. |
| References | PRT | Metabolism | Morphology | Flow Cytometry/activation markers | Functional tests | Comment | Conclusions |
|------------|-----|------------|------------|----------------------------------|------------------|---------|-------------|
| MIRASOL    | versus Control | Buffy-coat | Thrombolux ↓ 6–10 days | CD62 | ANV ↑ 2–10 days | ADP ↓ 2–10 days | Coll ↓ 2–10 days | Platelet quality decline during 10-day storage of standard and M-treated PCs in plasma. |
| Middelburg et al. | 10 days | — | — | 5–8 days | + TEG Angle = Max Ampl | — | — | |
| Zeddies et al. | —— | CD42b 5–8 days | CD41 = CD61 ↑ 5 days | PMA ↓ Convulxin ↓ R1 ↓ day 8 + Platelet spreading on Coll | Aggregation to convulxin and ristocetin was significantly lower and influenced by storage time. Spreading of platelets on Coll was reduced | M leads to hyperreactive PLTs, which aggregate and degranulate over storage time. |
| MIRASOL    | versus Control | Buffy-coat | Thrombolux ↓ 6–10 days | CD62 | ANV ↑ 2–10 days | ADP ↓ 2–10 days | Coll ↓ 2–10 days | Platelet quality decline during 10-day storage of standard and M-treated PCs in plasma. |
| Terada et al. | 5 days | — | — | 5–8 days | + TEG Angle = Max Ampl | — | — | |
| MIRASOL    | versus Control | Buffy-coat | Thrombolux ↓ 6–10 days | CD62 | ANV ↑ 2–10 days | ADP ↓ 2–10 days | Coll ↓ 2–10 days | Platelet quality decline during 10-day storage of standard and M-treated PCs in plasma. |
| Van Der Meer et al. | 8 days | — | — | 5–8 days | + TEG Angle = Max Ampl | — | — | |
| MIRASOL    | versus Control | Buffy-coat | Thrombolux ↓ 6–10 days | CD62 | ANV ↑ 2–10 days | ADP ↓ 2–10 days | Coll ↓ 2–10 days | Platelet quality decline during 10-day storage of standard and M-treated PCs in plasma. |
| ESCOLAR ET AL. | —— | Glucose ↓ 6–8 days | Lactate ↑ 6–8 days | HSR ↓ 6–8 | ANV ↑ 6–8 days | Coll ↓ 6–8 days | ADP ↓ 6–8 days | Storage in SSP+ after PRT has some beneficial action on pH, lactate |
|           |       | —— | — | 6–8 days | 6–8 days | 6–8 days | 6–8 days | Succinylated BPA was beneficial after PRT. |

(Continues)
### TABLE 1 (Continued)

| References          | PRT                              | Metabolism          | Morphology        | Flow Cytometry/activation markers | Functional tests | Comment                                                                 | Conclusions                                      |
|---------------------|----------------------------------|---------------------|-------------------|----------------------------------|------------------|------------------------------------------------------------------------|---------------------------------------------------|
| MIRASOL Ignatova et al.64 | versus Control or G-irradiation Apheresis Plasma SSP+ 5 days | —                   | Alterations 3–5 days | Pac-1 1–5 days CD62 1–5 days ANV 1–5 days Mitochondrial potential 0–5 days | Coll 1–5 days   | Further decline was observed being more pronounced for the units in SSP1 | Production an ANV expression                      |
| MIRASOL Terada et al.65 | Apheresis Before and after | —                   | —                 | —                                | —                | —                                                                      | Platelet Count ↓ (dilution) Clinical interventions in patients lower number of febrile reactions wit SSP+ stored PCs |
| MIRASOL Lachert et al.66 | versus Control Buffy-coat 5 days | Glucose 1–3 days pH 1–5 days HSR = CD42b = CD62 1 day B-tromboglobulin | — | Thrombus Formation on collagen Microfluidic Cone-plate Assay - | —                | PRT leads an immediate enhancement of PLT thrombus formation and thrombus stability on collagen. | Enhanced thrombus formation disappeared in the presence of αIIbb3 inhibitor. |
| MIRASOL Ballester-Servera et al.68 | versus Control Buffy-coat T-PAS + 14 days | Glucose 1–14 days Lactate 3–14 days pH 3–14 days Swirl 7–14 days | — | — | TEG R = Angle 7–14 days MA 7–14 | —                | Aggregation dropped after PRT, and further decreased in both groups at d 5 No statistical differences observed respect to control group | Platelet count ↓ Alterations in parameters after M comparable to those in control group |

PRT: Platelet Reservoir Therapy
| References | PRT | Metabolism | Morphology | Flow Cytometry/activation markers | Functional tests | Comment | Conclusions |
|------------|-----|------------|------------|-----------------------------------|-----------------|---------|-------------|
| Abbonnenc et al.67 | versus Control or UV Buffy-coat PAS+ versus PAS-IIIM 10 days | Glucose | HSR ↓ 2–7 days | PAC-1 ↑ 2–7 days | CD62↑ 2–7 days | ANV↑ 5–7 UV, M | ColI+P ↑ 7 days | The use of Epi, potentiated aggregating responses, but aggregation of PRT-PLTs was reduced at day 7. Platelet count ↓ with UV and PRT. PLTs more activated, showed, higher apoptosis markers and a lower HSR. PAS-IIIM preferable UV radiation alone is causing platelet lesions |
| INTERCEPT MIRASOL Picker et al.73 | Apheresis 8 days PAS | Glucose | = C | Swirl | CD62 ↑ 5–8 | ANV↑ 5–8 | Coll ↓ 7–8 days | M was significantly superior over I for HSR, aggregation with TRAP-6 | PRT-treated PLTs remained comparable to untreated units throughout 7 days of storage. Slightly better ATP maintenance and in vitro function for M during the last storage period |
| INTERCEPT MIRASOL Picker et al.73 | Triple dose Apheresis | CD41 | ↑ 5–8 days | CD62 | ↑ 5–8 days | — | TRAP ↓ 1–8 days | Aggregation ↓, no differences between study groups. Shear-induced adhesion significantly decreased in I units remained stable in M units during the entire 8-day observation period. | Irrespective of storage-related changes in PLT activation and turbidometric aggregation response, M-based PRT seemed to benefit shear-induced PLT adhesion |
| References | PRT | Metabolism | Morphology | Flow Cytometry/activation markers | Functional tests | Comment | Conclusions |
|------------|-----|------------|------------|-----------------------------------|------------------|---------|-------------|
| INTERCEPT, MIRASOL or UV alone Abonnenc et al.\textsuperscript{76} | Buffy-coat 8 days PAS Intersol | Glucose \(\text{5–7 days}\) Lactate \(\text{5–7 days}\) pH \(\text{5–7 days}\) for M or UV LDH \(\text{5–7 days}\) for I | HSR \(\text{\text{7 days}}\) PAC-1 \(\text{\text{2,7 days for I}}\) PAC-1 \(\text{\text{2,7 days for M or UV}}\) CD62 \(\text{\text{2,7 days for M or UV}}\) ANV \(\text{\text{2,7 days for M or UV}}\) | Adhesion on fibrinogen \(\text{\text{↑ from day 2, for M or UV}}\) | The capacity of riboflavin/UVB- and UVB-treated PLTs to adhere to fibrinogen decreased at the end of the storage period. | Platelet storage lesion is increased by M or UV compared to untreated PCs or I. These lesions are caused by the UVB radiation alone. |
| INTERCEPT MIRASOL or G-Irradiation Van Aelst et al.\textsuperscript{77} | 7 days | — | — | CD62 \(\text{\text{↑}}\) ANV \(\text{\text{↑}}\) Coll \(\text{\text{↓ 2–7 days, TRAP\textsuperscript{=}RI \text{\text{↓ 2–7 days M Coll \text{\text{↓ 2–7 days, TRAP\textsuperscript{=}RI \text{\text{↓ 2–7 days microfluidic chambers over immobilized collagen or VWF}}}}}}}}\) Coll \(\text{\text{↓ 2–7 days}}\) TRAP\(\text{=, RI \text{\text{↓ 2–7 days M Coll \text{\text{↓ 2–7 days, TRAP\textsuperscript{=}RI \text{\text{↓ 2–7 days microfluidic chambers over immobilized collagen or VWF}}}}}}\) | Both PRTs decreases the rate of thrombus formation in microfluidic flow chambers | I M mainly accelerate platelet storage lesion |
| THERAFLEX Mohr et al.\textsuperscript{19} | Buffy-coat UVC UVB versus G-irradiation 6 days PAS-IIIM | Glucose \(\text{6 days}\) Swirl \(\text{= HSR =}\) | — | CD62 \(\text{\text{↑}}\) ANV \(\text{\text{=}}\) Coll \(\text{\text{↓ 4–6 days}}\) | Aggregation with low concentrations collagen was impaired UVC UVB versus \(\gamma\)-irradiation Proteomic and Pathogen inactivation studies | Spontaneous aggregation 6 days. HIV-1 was only moderately inactivated |
| THERAFLEX Johnson et al.\textsuperscript{71} | versus Control Buffy-coat 7 days SSP+ | Glucose \(\text{7 days}\) HSR \(\text{\text{1–7 days}}\) PAC-1 \(\text{\text{1–7 days}}\) CD62 = ANV \(\text{\text{↑ 7 days Mitochondrial membrane = ADP = ColI = +}}\) | | Platelet aggregation was reduced but not | Reducing the plasma <30% did not significantly |
with enhanced expression of platelet activation markers and indicators of apoptosis. The type of bag and cell separator used may have some impact on quality parameters. Newer formulations of PAS may partially mitigate the effects of PRT when results are compared with those in classic PAS, but overall do not have a critical effect on the in vitro quality alterations.

Information on the impact of the newer THERAFLEX technology on the quality of platelets is sparse and mainly based on buffy-coat PCs (Figure 1). Metabolic and morphological changes in treated platelets follow the pattern described earlier for INTERCEPT or MIRASOL and run with moderate alterations in swirling and reduction of the HSR. Changes in the presence of glycoproteins, enhanced expression of P-selectin, and increased binding of annexin-V have also been reported, although they seem—relatively—less pronounced than with INTERCEPT or MIRASOL.

### 3.2 Modifications of functional responses

Table 1 summarizes a selected group of studies focused on the direct functional (adhesive, aggregating, or procoagulant) integrity of platelets in PCs subjected to PRT. Several studies have reported decreased aggregating response of platelets to ADP, collagen, or thrombin after INTERCEPT treatment, and to ADP, collagen, TRAP, or other agonists after MIRASOL treatment. Aggregating responses to ADP and collagen were reasonably preserved after THERAFLEX, although the published evidence with this technology is sparse relative to INTERCEPT or MIRASOL (Figure 1).

Studies under flow conditions allow for a more precise evaluation of adhesive and cohesive functionalities of platelets. In a model where reconstituted blood is perfused over damaged vascular segments, adhesive and aggregating properties of INTERCEPT-treated platelets were similar to control PCs and were well preserved for up to 7 days of storage. Stivala et al., however, reported that INTERCEPT reduced the adhesion and aggregation of platelets to von Willebrand factor-collagen substrata. MIRASOL-treated buffy-coat PCs preserved adhesive and cohesive functionalities comparable to the respective control PCs. Galan et al. evaluated the effect of MIRASOL on apheresis platelets during storage in PAS-III or PAS-IIIM in studies with flowing blood. Functional properties were preserved in PRT-treated concentrates stored in PAS for 5 days, with PAS-IIIM providing better preservation than PAS-III after 7 days of storage. In the cone-plate
approach, MIRASOL reduced platelet aggregation and surface coverage, with the responses decreasing with storage time similar to controls. In another set of flow studies measuring platelet interactions with collagen substrata, the authors found MIRASOL treatment enhanced platelet retention and increased thrombus formation on collagen surfaces. The enhanced thrombus formation disappeared in the presence of GPIIb-IIIa inhibitors indicating an early activation of this receptor by this PRT. THERAFLEX attenuated thrombus formation kinetics in vitro in microfluidic flow chambers, but only at later stages of storage. Overall, these data suggest that the PRT-induced functional reductions noted in in vitro aggregation assays are less pronounced in reconstituted blood samples subjected to shear rate conditions.

Thromboelastometric assays have been applied more recently to the global evaluation of the quality of PCs. These assays measure the viscoelastic properties of clot formation and subsequent lysis under low shear conditions and thereby reveal the contribution of thrombin generation, fibrinogen, platelet glycoproteins, and cytoskeletal assembly to the clot formation process. Studies have reported reductions in maximum clot strength in buffy-coat PCs stored in PAS solution exposed to MIRASOL. In a separate study, the viscoelastic parameters were minimally affected by THERAFLEX. Viscoelastic parameters require appropriate levels of fibrinogen and platelets in the test samples. Some of the cited studies used PCs stored in PAS that affect fibrinogen levels. Other studies have found alterations in viscoelastic parameters when storage time was extended beyond reasonable storage limits (14 days). Moreover, investigations using thromboelastography on buffy-coat PCs found that this methodology may lack sensitivity to detect normal storage-related quality changes.

3.3 | Comparative studies among PRTs

Picker et al. compared changes in quality parameters of PCs exposed to MIRASOL with those induced by gamma-irradiation and found the results with MIRASOL slightly better than their historical data with INTERCEPT. They concluded that PRT-treated apheresis PCs remained comparable to untreated ones in terms of integrity and morphology. Few studies have objectively compared INTERCEPT and MIRASOL technologies. MIRASOL was slightly superior to INTERCEPT for HSR and aggregation with TRAP-6. Studies on shear-induced adhesion found significant differences in favor of MIRASOL versus INTERCEPT. In contrast, platelet storage lesion was increased in MIRASOL-treated PCs versus untreated ones in another study. Interestingly, the latter study included a UV only arm as a control. The authors concluded that UV irradiation could be more accountable for the damaging actions of PRT than the riboflavin photosensitizer. In another study, exposure to MIRASOL or INTERCEPT caused differential impairments in platelet aggregating responses, although both treatments caused a reduction of platelet thrombus formation under flow conditions. The authors hypothesized that MIRASOL mainly accelerated platelet storage lesion, while INTERCEPT interfered more directly with mechanisms of platelet activation. Fveys et al. have also suggested that INTERCEPT or MIRASOL may impair platelet functions through different biochemical mechanisms. Although different mechanisms of action for the various PRTs, UV lengths, and photosensitizers are very likely, the hypothesis of selective changes by one or another PRT does not seem widely substantiated. Extensive evidence from numerous studies (Supplemental Table) indicates that different PRTs result in a similar pattern of modifications in the in vitro parameters of treated PCs.

4 | CHANGES IN THE PLATELET PROTEOME

Proteomic studies on standard PCs indicate that 97% of the proteins remain unchanged during storage but proteins related to the cytoskeletal and apoptotic functions show some changes. Schubert et al. identified 12 proteins, involved in cytoskeletal reorganization either as binding proteins to the actin filaments or as regulatory proteins for actin polymerization. Other studies reported alterations in signaling pathways involving ROS and post-translational modifications on phosphorylation mechanisms.

Study of proteomic changes induced by INTERCEPT in buffy-coat PCs found alterations of 23 and 58 proteins at days 1 and 5, respectively. Only three proteins showed consistent changes after treatment and storage: platelet endothelial aggregation receptor 1 precursor, protein tyrosine sulfotransferase 2 and CLIC4, another protein associated with cytoskeletal reorganization, apoptotic mechanisms, and oxidative stress. Prudent et al. reported a low impact on the proteome of INTERCEPT-treated platelets, affecting mainly proteins related to mitochondrial activity and oxidative stress. INTERCEPT PRT caused potential functional lesions involving the ADP receptor, CAMP synthesis, and PI3K, all crucial for platelet activation and aggregation.

With MIRASOL technology, Schubert et al. identified 26 proteins differentially expressed at day 6 of storage versus day of production and treatment. Proteins affected were also associated with the structure and
regulation of the cytoskeleton and with phosphorylation, of proteins linked to actin dynamics and regulation of GPIIb-IIIa activation. In treated apheresis PCs, Marrocco et al. investigated variations in protein profiles with gamma-irradiation or MIRASOL treatment. According to this proteomic analysis, gamma-irradiation results in the acceleration of the PLT storage lesions and MIRASOL treatment only moderately exacerbated these phenomena. Salunkhe et al. found significant changes at the proteome level after MIRASOL that were essentially related to the functional aspects described to affect current PCs during storage. In treated apheresis PCs, MIRASOL altered 26 unique proteins. Interestingly, this study demonstrated for the first time that platelets can synthesize proteins despite riboflavin and UV treatment and suggested that platelets may possess a mechanism to protect their mRNA from damage by the PRT. Further studies on day 2 of storage in PCs prepared from buffy-coats in PAS exposed to MIRASOL found a high proportion of oxidations in platelet proteins with additional interference on several cytoskeletal proteins involved in platelet aggregation.

Mohr et al. evaluated the impact of THERAFLEX UVC on the platelet proteome in comparison with UVB alone or gamma-irradiation. The study found 67 proteins modified by UVB treatment, 48 by UVC, and 87 by gamma-irradiation, in the treated samples compared to controls. Proteome analysis revealed a common set of 92 protein spots affected by all three types of irradiation. Specific alterations were most pronounced for gamma-irradiation, followed by UVB and UVC.

In a comparative study, Prudent et al. investigated the oxidative damages produced by INTERCEPT and MIRASOL on model peptides. MIRASOL was found to generate more oxidation than INTERCEPT, and triggered dysregulation of cell signaling, alteration of the cytoskeleton, and the redox metabolism. Similar modifications had been reported in previous studies on INTERCEPT-treated PCs. In another comparative review, the authors merged the key findings of the proteomic analyses of INTERCEPT-, MIRASOL-, and THERAFLEX-treated PCs. The study concluded that all PRTs had a relatively weak impact on the overall proteome of platelets.

5 | A CRITICAL APPRAISAL OF THE IN VITRO DATA AND ITS SIGNIFICANCE

A bibliometric analysis of the proportion of studies evaluating different aspects of the in vitro quality of PCs exposed to PRTs reveals more abundant information on MIRASOL, with studies on qualitative aspects (glycoprotein alterations or thromboelastometry) that are lacking for INTERCEPT or THERAFLEX (Figure 1). It should be noted that the extent of information available for a particular PRT technology does not correlate with its impact on the in vitro quality of treated platelet product. The bibliometric evaluation also reveals that the majority of studies have utilized indirect platelet quality surrogates, and few have used direct functional parameters, thus indicating that functional studies are more complex to perform.

Modifications of metabolic, functional, and proteomic parameters in PRT-exposed PCs are consistent with an acceleration of the classically described storage lesion. Despite the metabolic alterations, final pH and platelet number in PCs after PRTs still meet the criteria of regulatory authorities. Moreover, pO2 and pCO2 levels confirm proper gas exchange in the stored PCs, both control and PRT-treated.

Moderate quantitative modifications in the GPs detected by flow cytometry, despite significant, should not have dramatic impact on the hemostatic response of platelets. It is well established in heterozygotic forms of Bernard-Soulier’s or Glanzmann’s thrombasthenia that platelets that possess half the amount of GPIb or GPIIb-IIIa have normal hemostatic performance. It is possible that receptor-mediated signaling mechanisms affected by the storage and PRTs may have an additional impact on functional responses. Increase in platelet activation markers in pathogen-reduced platelets is an indicator of the development of apoptotic mechanism. However, if these changes only represent natural apoptosis, they should not necessarily indicate a critical reduction in platelet function. Partially activated platelets can still be effective in the treatment of active bleeding.

Overall, patterns of metabolic and functional alterations observed with different PRTs were indistinguishable. The impact of PRTs on the overall proteome of platelets is relatively low, with various studies indicating that PRTs accelerate the common storage lesion. Despite particular interpretations, a distinctive proteomic fingerprint has not been reported for any of the PRTs investigated until now. Interestingly, alterations of the proteomic and metabolic profiles in platelets exposed to PRTs are comparable or less than the ones observed in currently gamma-irradiated PCs.

6 | CLINICAL STUDIES

Preliminary studies with radio-labeled platelets given as autologous transfusions to healthy volunteers indicated that platelets treated with INTERCEPT, MIRASOL, or THERAFLEX had a slightly decreased recovery and
Pathogen-reduced PCs have been studied for their clinical effectiveness in 11 randomized controlled clinical trials, seven with INTERCEPT, three with MIRASOL, and one with THERAFLEX-treated platelets. The trials involved more than 2900 patients—1900 patients in RCT with INTERCEPT, 860 patients with MIRASOL, and 87 with THERAFLEX. Both buffy-coat and apheresis platelets have been used for the different PRTs with platelets suspended in plasma or PAS. A tabular review from all RCTs published by December 2018 is available.

The corrected count increments (CCIs) in patients receiving PRT-treated platelets were consistently lower than in control patients at both 1 and 24 h following transfusion (Table 2). CCIs seemed slightly better in the more recent clinical study with THERAFLEX although a higher dose of platelets (>25% vs. control platelets) was used. The total dose of treated platelets needed was in general larger than the dose required of control platelets and the transfusion intervals shorter for treated PCs. With the exception of one smaller study in which patients receiving PCs treated with INTERCEPT experienced more bleeds, the overall results of larger studies showed no significant differences in the rates of higher bleeding among patients receiving platelets subjected to PRTs vs. conventional platelets. The number of red blood cells received by patients was similar between treated and untreated platelet recipients in all RCTs, confirming the absence of differences in excessive bleeding. In either case, the important point is no relative difference in bleeding results from transfusion of all kinds of PR platelets. Thus, in this large number of RCTs, PCs exposed to PRTs showed as hemostatically effective as conventional ones.

The rates of transfusion reactions were similar in patients receiving PCs exposed to PRTs or control platelets. In all RCTs, there were no statistically significant differences in the overall rate of transfusion reactions. A Cochrane meta-analysis published in 2017 reported findings from 2075 patients randomized in 12 trials to receive untreated platelets or exposed to PRTs. The analysis concluded that there were no differences between PRT-treated platelets and standard platelets in the incidence of all-cause mortality at 4–12 weeks. No differences in the incidence of serious adverse events were observed. There is clear evidence that patients receiving pathogen-reduced platelet transfusions required more frequent platelet transfusion and were at a higher risk of developing platelet refractoriness. Remarkably, no transfusion-transmitted bacterial infections occurred in the trials that reported this outcome. For long-term safety, manufacturers carry out extensive hemovigilance studies to continuously document and characterize the safety profile of INTERCEPT and MIRASOL platelets. More than 875,000 INTERCEPT PCs have been transfused to patients in various countries, with no reported transfusion-transmitted infections or sepsis-related fatalities. More than 700,000 MIRASOL units have been transfused. No serious adverse events have been reported with the use of MIRASOL-treated platelets or plasma. Thus, the clinical efficacy and safety profile of PR platelets prepared with both INTERCEPT and MIRASOL appear to be satisfactory and similar.

7 | FUTURE PROSPECTS

It would be desirable that PRTs could be adapted not only to platelets, but also to other blood products including whole blood. MIRASOL, the alkylation agent S-303 and THERAFLEX are being investigated for pathogen reduction in red blood cell concentrates and whole blood. INTERCEPT and MIRASOL are being evaluated in phase III clinical trials, while some experimental approaches are underway with THERAFLEX. In a landmark study, MIRASOL PRT whole blood has been successfully used to prevent transmission of malaria in endemic regions. This is the only trial that has shown prevention of actual transfusion-transmitted infection.

New platelet products such as cold stored, cryopreserved, or substitutive will become increasingly available. PRTs use is being explored with these new products. The combined implementation of cold- or cryopreservation methodologies with PRTs would help optimize different platelet products for specific clinical purposes. New pathogen reduction strategies are being investigated using novel photosensitizers and illuminations with wavelengths in the blue (400–450 nm) or red light 600–737 nm) spectrum.

There is a lack of studies evaluating a possible synergistic detrimental action of PRTs in combination with gamma-irradiation. Although several in vitro studies referred in this review have evaluated the impact of gamma-irradiation or PRT comparatively with INTERCEPT or MIRASOL, none of them has investigated a possible negative impact of combining PRT plus gamma-irradiation. A measurable adverse effect of irradiation on ex vivo platelet aggregation was reported earlier. Although it is generally accepted not to cause critical modifications on the in vitro quality of platelets, gamma-irradiation of PCs produces similar metabolic changes as have been observed after PRTs. Remarkably, molecular studies suggest that gamma-irradiation causes more pronounced changes in the platelet proteome than INTERCEPT, MIRASOL, or THERAFLEX. Gamma-irradiated PCs have been
**Table 2** Descriptive information for the different clinical trials using platelet concentrates treated with different PRTs

| Technology acronym | Description/type of study                                                                 | 1-h CCI reference treatment | Reduction % | 24-h CCI reference treatment | Reduction % |
|--------------------|------------------------------------------------------------------------------------------|-----------------------------|-------------|-----------------------------|-------------|
| INTERCEPT EuroSPRITE⁹⁷ | Controlled, randomized, double-blinded trial 103 patients PRT (311 transfusions) vs. control (256 transfusions) | 14,900 | 13,100 | 12% | 10,600 | 7400 | 30% |
| INTERCEPT SPRINT⁹⁸    | Patients randomly assigned, 645 patients (318 PCT and 327 control)-PRT 280 versus control 294- | 16,000 | 11,100 | 31% | 10,100 | 6700 | 33% |
| INTERCEPT Janetzko⁹⁹   | Multicenter, randomized, controlled, double-blind 43 patients PRT 86 versus control 107 | 15,100 | 11,600 | 23% | |
| INTERCEPT HOVON ⁸²¹⁰⁻ Plasma | Randomized open-label non-inferiority 278 patients 99 plasma, 85 PRTPAS-III 357 Plasma, 257 PRT PAS-III | 17,100 | 10,600 | 38% | 12,500 | 6800 | 46% |
| INTERCEPT HOVON ⁸²¹⁰⁻ PAS-III | Randomized open-label non-inferiority 278 patients 94 PAS-III, 85 PRTPAS-III 278 PAS-III 257 PRT PAS-III | 15,300 | 10,600 | 31% | 11,700 | 6800 | 42% |
| INTERCEPT TESSI¹⁰¹ | Randomized, controlled, double-blinded 201 patients 101 PRT versus 100 controls | 9383 | 8163 | 13% | | |
| INTERCEPT IPTAS¹⁰² | Randomized, non-inferiority, controlled 228 patients 113 treated versus 115 controls 667 PRT-PLTs versus 441 reference | 11,391 | 9387 | 18% | 9153 | 6087 | 34% |
| INTERCEPT Effipap¹⁰³ | Randomized, non-inferiority, 3-arm 126 PRT PAS versus 262 Controls plasma | — | — | — | 10,200 | 5000 | 51% |
| INTERCEPT Effipap¹⁰³ | Randomized, non-inferiority, 3-arm 126 PRT versus 120 Controls PAS | — | — | — | 8200 | 5000 | 39% |
| Average values       |                                                                                           | 14,167 ± 2746 | 10,647 ± 1575 | 24.8% | 9875 ± 1901 | 6047 ± 1050 | 38.1% |
| Technology acronym | Description                                                                 | 1-h CCI reference treatment | Reduction % | 24-hour CCI reference treatment | Reduction % |
| MIRASOL MIRACLE ¹⁰⁴ | Multicenter, randomized controlled trial. 541 on-protocol PLT transfusions (303 PRT-PLTs; 238 reference) | 16,939 | 11,725 | 31% | 9886 | 6676 | 32% |
| MIRASOL IPTAS¹⁰² | Randomized, non-inferiority, controlled 196 patients 99 treated versus 97 controls 457 PRT-PLTs versus 457 reference | 17,639 | 12,357 | 30% | 8605 | 6051 | 30% |
| MIRASOL PREPAREs¹⁰⁵ | Randomized, multicenter non-inferiority, parallel arm design 469 patients 284 PRT-PLTs, 283 reference transfusions) | 13,000 | 8000 | 39% | 7000 | 4000 | 43% |
| Average value       |                                                                                           | 15,859 ± 2501 | 10,694 ± 2354 | 33.3% | 8497 ± 1446 | 5576 ± 1400 | 35% |
| THERAFLEX CAPTURE¹⁰⁶ | Randomized, controlled, double-blind, non-inferiority, multicenter − 87 treated versus 84 controls 320 PRT-PLTS, 248 control transfusions | 15,530 ± 6,090 | 12,700 ± 5,98 | 18.2% | 10,850 ± 6,160 | 8770 ± 5,520 | 19.2% |
sporadically used in the different RCTs with PRTs. Unfortunately, the results and numbers of patients who received irradiated and non-irradiated blood have not been homogeneously reported or segregated in the different RCTs so it is not possible to determine whether gamma-irradiation had any clinical effect. The possible synergistically detrimental action of PRT plus gamma irradiation should be further investigated. Presently, PCS are gamma irradiated to prevent transfusion-associated graft versus host disease (TA-GVHD). A recognized additional benefit of PRT would be in the prevention of this unwanted complication. Early experimental studies demonstrated that MIRASOL inactivated the immunologic responses mediated by leukocytes and prevented the development of GVHD in a mouse model. Further observations have shown that non-irradiated PRT-blood components do not cause TA-GVHD. No case of transfusion-related acute lung injury or TA-GVHD has been attributed to the transfusion of PCs exposed to PRT. Thus, the need for both treatments should be reconsidered since the implementation of PRTs alone precludes the necessity for irradiating cellular components to prevent TA-GVHD.

8 | CONCLUSIONS

The large number of in vitro studies examined confirms that PRT technologies have a homogeneous and interchangeable detrimental action on the in vitro quality parameters of treated PCs when they are compared with non-treated products. PRTs have a relatively low impact on the overall proteome of platelets with results from different studies confirming that these technologies accelerate the classic storage lesion. Surprisingly, gamma-irradiation seems to have a more profound impact on proteomic modifications than current PRTs.

RCTs with platelets subjected to PRTs indicate a moderate deterioration of platelet quality and reduced survival in the transfused patients. Post-transfusion count increments are lower and the transfusion interval shorter for patients receiving PCs treated with either kind of PRTs. However, by far the most important issue is that the trials establish that the ability of treated platelets to control bleeding is equal to control platelets in routine use.

In summary, PRTs add a supplementary level of safety to current donor screening and regulated testing for known pathogens. These technologies increase patient safety at the expense of some platelet functional and survival losses in clinical trials. It has been claimed that researchers and health organizations have been crying wolf on possible infectious threats based on false alarms and patient safety. Limitations in the extent of previous infectious outbreaks and their specific geographical localization may have given a misinterpretation of their real threat. COVID-19 is a closer call, a deadly infectious disease sweeping across the world. COVID-19 does not seem to be transmitted through blood components, but is warning our health systems that global expansion of emerging infections is real. The current approach of donor screening and blood testing for known pathogens has dramatically improved the safety of transfused blood products. With increasing globalization, climate change, and the unpredictability of emerging pathogens, the proactive implementation of PRTs that could be adapted to treat platelets, red blood cells or whole blood should be considered. PRTs will be valuable for virtually all infectious emerging agents and would certainly increase safety against blood-transmissible future threats.

ACKNOWLEDGMENTS

Marcia Cardoso (Terumo BCT) for her helpful comments and also to M. Urooj Zafar), Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, for his help.

CONFLICT OF INTEREST

Gines Escolar has received honoraria/consultant fees from Bayer, BMS, Boehringer Ingelheim, CSL Behring, Grifols S.A., and Terumo (BCT); Maribel Diaz-Ricart has been granted by Jazz Pharmaceuticals, Bristol Myers Squibb/Pfizer, and received honoraria from Siemens Healthineers and Jazz Pharmaceuticals. Jeffrey McCullough has received advisory fees from Terumo BCT, Fresenius Kabi, and Haemonetics.

ORCID

Jeffrey McCullough https://orcid.org/0000-0002-8730-3981

REFERENCES

1. Atreya C, Glynn S, Busch M, Kleinman S, Snyder E, Rutter S, et al. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (commentary, p. 3026). Transfusion. 2019;59:3002–25.
2. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(Suppl 2):1S–29S.
3. Klein HG. Pathogen inactivation technology: cleansing the blood supply. J Intern Med. 2005;257:224–37.
4. Alter HJ. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev. 2008;22:97–102.
5. Wieding JU, Hellstern P, Kohler M. Inactivation of viruses in fresh-frozen plasma. Ann Hematol. 1993;67:259–66.
6. Blajchman MA. Bacterial contamination of cellular blood components: risks, sources, and control. Vox Sang. 2004;87-(Suppl 1):98–103.
7. Ciaravi V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20:533–50.
8. Goodrich RP. Use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000;78(Suppl 2):211–5.
9. Sellsam A, Muller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother. 2011;38:43–54.
10. McCullough J, Alter HJ, Ness PM. Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion. 2019;59:1132–46.
11. Goodrich RP, Custer B, Keil S, Busch M. Defining “adequate” pathogen reduction performance for transfused blood components. Transfusion. 2010;50:1827–37.
12. Nahler G. Committee for Proprietary Medicinal Products (CPMP). Dicr Pharm Med. 2009;32.
13. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang. 2013;104:183–99.
14. Kaiser-Guignard J, Canellini G, Lion N, Abonnenc M, Osselaer JC, Tissot JD. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood. Rev. 2014;28:235–41.
15. Isisch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother. 2011;38:19–31.
16. Lanteri MC, Santa-Maria F, Laughhunn A, Girard YA, Picard-Maureau M, Payrat JM, et al. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet a light. Transfusion. 2020;60:1319–31.
17. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–85.
18. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35:5–17.
19. Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion. 2009;49:2612–24.
20. Laughhunn A, Santa Maria F, Broult J, Lanteri MC, Stassinopoulos A, Musso D, et al. Amotosaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. Transfusion. 2017;57:779–89.
21. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci. 2008;39:75–82.
22. Keil SD, Ragan I, Yonemura S, Hartson L, Dart NK, Bowen R. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang. 2020;115:495–501.
23. Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS One. 2020;15:e0233947.
24. Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion. 1991;31:409–14.
25. Escolar G, McCullough J. Platelet in vitro assays: their correspondence with their in vivo hemostatic potential. Transfusion. 2019;59:3783–93.
26. Procaccini EM, Pandolfi G, Monfrecola G, Rotoli B. Effect of psoralen and ultraviolet a on platelet functioning: an in vitro and in vivo study. Photodermatol Photomed. 1992;9:4–7.
27. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423–35.
28. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived fromuffy coats. Vox Sang. 2000;79:206–14.
29. Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209–16.
30. Picker SM, Speer R, Gathoff BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion. 2004;44:320–9.
31. Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Kluter H. Implementation of the INTERCEPT blood system for platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang. 2004;86:239–45.
32. Jansen GA, van Vliet HH, Vermeij H, et al. Functional characteristics of photochemically treated platelets. Transfusion. 2004;44:313–9.
33. Carvalho H, Alguedo C, Santos M, de Sousa G, Trindade H, Seghatchian J. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience. Transfus Apher Sci. 2006;34:187–92.
34. Lozano M, Galan A, Mazzara R, Corash L, Escolar G. Leuko-reduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet a light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion. 2007;47:666–71.
35. Chavarin P, Cognasse F, Argaud C, Vidal M, de Putter C, Boussoulaide F, et al. In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT blood system). Vox Sang. 2011;100:247–9.
36. Johnson L, Loh YS, Kwok M, Marks DC. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT blood system. Transfus Med. 2013;23:121–9.
37. Vethesen A, Mirlashari MR, Akkok CA, et al. Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates. Transfusion. 2013;53:147–55.
38. Sandgren P, Diedrich B. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with
amotosalen and UVA light: preservation of in vitro function. Vox Sang. 2015;108:340–9.

39. Castrillo A, Alvarez I, Tolksdorf F. In vitro evaluation of platelet concentrates suspended in additive solution and treated for pathogen reduction: effects of clumping formation. Blood Transfus. 2015;13:281–6.

40. Abonnenc M, Sonego G, Kaiser-Guignard J, Crettaz D, Prudent M, Tissot JD, et al. In vitro evaluation of pathogen-inactivated Buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfus. 2015;13:255–64.

41. Stivala S, Gobbato S, Infant L, Reiner MF, Bonetti N, Meyer SC, et al. Amotosalen/ultraviolet a pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica. 2017;102:1650–60.

42. Feys HB, Devloo R, Sabot B, de Pourcq K, Coene J, Compermoole V. High platelet content can increase storage lesion rates following intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis. Vox Sang. 2017;112:751–8.

43. Lotens A, de Valensart N, Najdovski T, Acquart S, Cognasse F, Rapaille A. Influence of platelet preparation techniques on in vitro storage quality after psoralen-based photochemical treatment using new processing sets for triple-dose units. Transfusion. 2018;58:2942–51.

44. Ohlsson S, Diedrich B, Uhlin M, Sandgren P. Optimized processing for pathogen inactivation of double-dose Buffy-coat platelet concentrates: maintained in vitro quality over 7-day storage. Vox Sang. 2018;113:611–21.

45. Castrillo Fernandez A, Lanteri MC, Arcas Otero C, et al. In vitro evaluation of pathogen inactivated platelet quality: an 8 year experience of routine use in Galicia. Spain Transfus Apher Sci. 2019;58:87–93.

46. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45:1335–41.

47. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45:911–9.

48. Picker SM, Steisel A, Gathof BS. Effects of mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion. 2008;48:1685–92.

49. Janetzko K, Hinz K, Marschner S, Goodrich R, Kluter H. Evaluation of different preparation procedures of pathogen reduction technology(Mirasol(R))-treated platelets collected by Plateletpheresis. Transfus Med Hemother. 2009;36:309–15.

50. Janetzko K, Hinz K, Marschner S, Goodrich R, Kluter H. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang. 2009;97:234–9.

51. Picker SM, Steisel A, Gathof BS. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci. 2009;40:79–85.

52. Reikvam H, Marschner S, Apelseth TO, Goodrich R, Hervig T. The Mirasol pathogen reduction technology system and quality of platelets stored in platelet additive solution. Blood Transfus. 2010;8:186–92.

53. Ostrowski SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, et al. In vitro cell quality of Buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion. 2010;50:2210–9.

54. Ostrowski SR, Bochsen L, Windelov NA, et al. Hemostatic function of Buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion. 2011;51:344–56.

55. Galan AM, Lozano M, Molina P, Navalon F, Marschner S, Goodrich R, et al. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion. 2011;51:808–15.

56. Johnson L, Winter KM, Reid S, Hartkopf-Theis T, Marschner S, Goodrich RP, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang. 2011;101:208–14.

57. Cookson P, Thomas S, Marschner S, Goodrich R, Cardigan R. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion. 2012;52:983–94.

58. Picker SM, Tauszig ME, Gathof BS. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion. 2012;52:510–6.

59. Mastroianni MA, Llohn AH, Akkoc CA, et al. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets. Transfus Apher Sci. 2013;49:285–90.

60. Middelburg RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, van der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion. 2013;53:1780–7.

61. Zeddies S, De Cuypier IM, van der Meer PF, et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion. 2014;54:2292–300.

62. Terada C, Mori J, Okazaki H, Satake M, Tadokoro K. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation on collagen via integrin alphaHbeta3 activation. Transfusion. 2014;54:1808–16.

63. van der Meer PF, Bontekoe IJ, Daal BB, de Korte D. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution? Transfusion. 2015;55:1900–8.

64. Ignatova AA, Karpova OV, Trakhtman PE, Rumiantsev SA, Panteleev MA. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Vox Sang. 2016;110:244–52.

65. Terada C, Shibata M, Nagai T, Satake M. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation and thrombus stability on collagen. Transfusion. 2017;57:1772–80.

66. Lachert E, Kubis J, Antoniewicz-Papis J, Rosiek A, Woźniak J, Piotrowski D, et al. Quality control of riboflavin-treated platelet concentrates using Mirasol(R) PRT system: polish experience. Adv Clin Exp Med. 2018;27:765–72.

67. Abonnenc M, Crettaz D, Sonego G, Escolar G, Tissot JD, Prudent M. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol(R)-treated platelets. Transfus Clin Biol. 2019;26:209–16.
68. Ballester-Servera C, Jimenez-Marcos T, Morrell-Garcia D, Quetglas-Oliver M, Bautista-Gili AM, Girona-Llobera E. Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light. Blood Transfus. 2020;18:280–9.

69. Bashir S, Cookson P, Wiltshire M, Hawkins L, Sonoda L, Thomas S, et al. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion. 2013;53:990–1000.

70. Sandgren P, Tolksdorf F, Struff WG, Guilliksson H. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-platelets method. Vox Sang. 2011;101:35–43.

71. Johnson L, Hyland R, Tan S, Tolksdorf F, Sumian C, Seltsam A, et al. In vitro quality of platelets with low plasma carryover treated with ultraviolet C light for pathogen inactivation. Transfus Med Hemother. 2016;43:190–7.

72. van der Meer PF, Gravemann U, de Korte D, Sumian C, Abonnenc M, Sonego G, Crettaz D, Aliotta A, Prudent M, Lion N. Proteomic analysis of platelets treated with pathogen reduction technologies. Transfusion. 2013;53:1808–20.

73. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang. 2009;97:26–33.

74. Picker SM, Schneider V, Oustianskaia L, Gathof BS. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion. 2009;49:2311–8.

75. Picker SM, Schneider V, Gathof BS. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion. 2009;49:1224–32.

76. Abonnenc M, Sonego G, Crettaz D, Aliotta A, Prudent M, Tissot JD, et al. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfus. 2015;55:2219–30.

77. Van Aelst B, Feys HB, Devloo R, et al. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang. 2015;108:328–39.

78. Arbaeen AF, Serrano K, Levin E, Devine DV. Platelet concentrate functionality assessed by thromboelastography or rotational thromboelastometry. Transfusion. 2016;56:2790–8.

79. Feys HB, Van Aelst B, Compernolle V. Biomolecular consequences of platelet pathogen inactivation methods. Transfus Med Rev. 2019;33:29–34.

80. Thiele T, Steil L, Gebhard S, Scharf C, Hammer E, Brigulla M, et al. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion. 2007;47:1221–33.

81. Schubert P, Thon JN, Walsh GM, Chen CHI, Moore ED, Devine DV, et al. A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration. Transfusion. 2009;49:1944–53.

82. Sonego G, Abonnenc M, Tissot JD, Prudent M, Lion N. Redox proteomics and platelet activation: understanding the redox proteome to improve platelet quality for transfusion. Int J Mol Sci. 2017;18.

83. Thiele T, Sablewski A, Iuga C, et al. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation—a LC-ESI-MS/MS-based proteomics approach. Blood Transfus. 2012;10(Suppl 2):s63–70.

84. Prudent M, Crettaz D, Deolobe J, et al. Proteomic analysis of intertreat treated platelets. J Proteomics. 2012;76:316–28.

85. Schubert P, Culibrk B, Coupland D, Scammell K, Gygongyosy-Issa M, Devine DV, Riboflavin and ultraviolet light treatment potentiate vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion. 2012;52:397–408.

86. Marrococ C, D’Alessandro A, Girelli G, Zolla L. Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion. 2013;53:1808–20.

87. Salunkhe V, De Cuyper IM, Papadopoulos P, et al. A comprehensive proteomics study on platelet concentrates: platelet proteome, storage time and Mirasol pathogen reduction technology. Platelets. 2019;30:368–79.

88. Schubert P, Culibrk B, Karwal S, Goodrich RP, Devine DV. Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment. Proteomics Clin Appl. 2016;10:839–50.

89. Sonego G, Abonnenc M, Crettaz D, Lion N, Tissot JD, Prudent M. Irreversible oxidations of platelet proteins after riboflavin-UVB pathogen inactivation. Transfus Clin Biol. 2020;27:36–42.

90. Prudent M, Sonego G, Abonnenc M, Tissot JD, Lion N. LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. J Am Soc Mass Spectrom. 2014;25:651–61.

91. Prudent M, D’Alessandro A, Cazenave JP, et al. Proteome changes in platelets after pathogen inactivation—an interlaboratory consensus. Transfus Med Rev. 2014;28:72–83.

92. van Zanten GH, Heijnen HF, Wu Y, et al. A fifty percent reduction of platelet surface glycoprotein Ib does not affect platelet adhesion under flow conditions. Blood. 1998;91:2353–9.

93. Fabris F, Casonato A, Randi ML, Luzzatto G, de Silvestro G, Ongaro G, et al. The use of fluorescence flow cytometry in the characterization of Bernard-Soulier syndrome and Glanzmann’s thrombasthenia. Haematologica. 1989;74:39–44.

94. Estebanell E, Diaz-Ricart M, Escolar G, Lozano M, Mazzara R, Ordinas A. Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method. Transfusion. 2000;40:535–42.

95. Ness PM. Platelets from the refrigerator: a better way to stop bleeding? Annals Blood. 2019;4:1–4.

96. Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M, et al. Recovery and life span of 111indium-radiolabeled platelets. J Am Soc Mass Spectrom. 2014;25:651–61.

97. van Rhenen D, Gullickson H, Cazenave JP, Pamphilon D, Ljungman P, Klöter H, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101:2426–33.
platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104:1534–41.
99. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion. 2005;45:1443–52.
100. Kerkhoffs JL, van Putten WL, Novotny VM, te Boekhorst PA, Schipperus MR, Zwagginga JJ, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150:209–17.
101. Lozano M, Knutson F, Tardivel R, Cid J, Maymó RM, Löf H, et al. A multi-Centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet a pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol. 2011;153:393–401.
102. Rebulla P, Vaglio S, Beccaria F, Bonfichi M, Carella A, Chiurazzi P, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion. 2017;57:117–83.
103. Garban F, Guyard A, Labussiere H, et al. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol. 2018;4:468–75.
104. Mirasol clinical evaluation study G. a randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50:2362–75.
105. van der Meer PF, Ypma PF, van Geloven N, van Hilten JA, Wordragen-Vlaswinkel RJ, Eissen O, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood. 2018;132:223–31.
106. Brixner V, Bug G, Pohler F, Krämer D, Metzner B, Voss A, et al. Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial. Haematologica. 2021;106:1086–96.
107. Rebulla P, Garban F, van der Meer PF, et al. A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets. Transfusion. 2020;60:1267–77.
108. Estcourt LJ, Malouf S, Hopewell S, Trivella M, Doree C, Stanworth SJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2017;7:CD009072.
109. Drew VJ, Barro L, Seghatchian J, Burnouf T. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus. 2017;15:512–21.
110. Handke WD, Gravemann U, Muller T, Selsams A. Pathogen inactivation of red blood cells by ultraviolet C light. Vox Sang. 2019;114:164.
111. Allain JP, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S. Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African investigation of the Mirasol system (AIMS) randomised controlled trial. Lancet. 2016;387:1753–61.
112. Waters L, Cameron M, Padula MP, Marks DC, Johnson L. Refrigeration, cryopreservation and pathogen inactivation: an updated perspective on platelet storage conditions. Vox Sang. 2018;113:317–28.
113. Sow C, Laughhunn A, Girard YA, Lanteri MC, Amar el Dusouqui S, Stassinopoulos A, et al. Inactivation of plasmodium falciparum in whole blood using the amastoline and glutathione pathogen reduction technology. Transfusion. 2020;60:799–805.
114. Hadj J, Dunowska M, Wu S, Brightwell G. Control measures for SARS-CoV-2: a review on light-based inactivation of single-stranded RNA viruses. Pathogens. 2020;9.
115. Sweeney JD, Holme S, Moroff G. Storage of apheresis platelets after gamma radiation. Transfusion. 1994;34:779–83.
116. van der Meer PF, Pietersz RN. Gamma irradiation does not affect 7-day storage of platelet concentrates. Vox Sang. 2005;89:97–9.
117. Tynngard N, Studer M, Lindahl TL, et al. The effect of gamma irradiation on the quality of apheresis platelets during storage for 7 days. Transfusion. 2008;48:1669–75.
118. Mallhi RS, Biswas AK, Philip J, Chatterjee T. To study the effects of gamma irradiation on single donor apheresis platelet units by measurement of cellular counts, functional indicators and a panel of biochemical parameters, in order to assess pre-transfusion platelet quantity and quality during the shelf life of the product. Med J Armed Forces India. 2016;72:19–26.
119. Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-platelets pathogen inactivation system - an update. Transfus Apher Sci. 2012;46:221–9.
120. Fast LD, DiLeonie G, Cardarelli G, et al. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneric graft-versus-host disease in Rag2−/−/gamma c−/− double knockout mice. Transfusion. 2006;46:1553–60.
121. Mintz PD, Wehrli G. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant. 2009;44:205–11.
122. Knutson F, Osselaer J, Piereilli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang. 2015;109:343–52.
123. Watson R. WHO is accused of “crying wolf” over swine flu pandemic. BMJ. 2010;340:c1904.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Escolar G, Diaz-Ricart M, McCullough J. Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic. Transfusion. 2022;62:227–46. https://doi.org/10.1111/trf.16747